Your browser doesn't support javascript.
loading
Non-permissive SARS-CoV-2 infection in human neurospheres.
Pedrosa, Carolina da S G; Goto-Silva, Livia; Temerozo, Jairo R; Souza, Leticia R Q; Vitória, Gabriela; Ornelas, Isis M; Karmirian, Karina; Mendes, Mayara A; Gomes, Ismael C; Sacramento, Carolina Q; Fintelman-Rodrigues, Natalia; Cardoso Soares, Vinicius; Silva Gomes Dias, Suelen da; Salerno, José A; Puig-Pijuan, Teresa; Oliveira, Julia T; Aragão, Luiz G H S; Torquato, Thayana C Q; Veríssimo, Carla; Biagi, Diogo; Cruvinel, Estela M; Dariolli, Rafael; Furtado, Daniel R; Borges, Helena L; Bozza, Patrícia T; Rehen, Stevens; Moreno L Souza, Thiago; Guimarães, Marília Zaluar P.
Afiliación
  • Pedrosa CDSG; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Goto-Silva L; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Temerozo JR; National Institute for Science and Technology on Neuroimmunomodulation (INCT/NIM), Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; Laboratory on Thymus Research, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Souza LRQ; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Vitória G; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Ornelas IM; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Karmirian K; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Mendes MA; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Gomes IC; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Sacramento CQ; Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cru
  • Fintelman-Rodrigues N; Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cru
  • Cardoso Soares V; Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; Program of Immunology and Inflammation, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Silva Gomes Dias SD; Immunopharmacology Laboratory, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Salerno JA; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Puig-Pijuan T; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Oliveira JT; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Aragão LGHS; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Torquato TCQ; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Veríssimo C; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Biagi D; Pluricell Biotech, São Paulo, SP, Brazil.
  • Cruvinel EM; Pluricell Biotech, São Paulo, SP, Brazil.
  • Dariolli R; Pluricell Biotech, São Paulo, SP, Brazil; Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Furtado DR; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil.
  • Borges HL; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.
  • Bozza PT; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil.
  • Rehen S; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil; Institute of Biology, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil. Electronic address:
  • Moreno L Souza T; National Institute for Science and Technology on Innovation in Diseases of Neglected Populations (INCT/IDPN), Center for Technological Development in Health (CDTS), Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, RJ, Brazil; Program of Immunology and Inflammation, Federal University of Rio de Jan
  • Guimarães MZP; D'Or Institute for Research and Education (IDOR), Rio de Janeiro, RJ, Brazil; Institute of Biomedical Sciences, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil. Electronic address: marilia@lance-ufrj.org.
Stem Cell Res ; 54: 102436, 2021 07.
Article en En | MEDLINE | ID: mdl-34186311
Coronavirus disease 2019 (COVID-19) was initially described as a viral infection of the respiratory tract. It is now known, however, that several other organs are affected, including the brain. Neurological manifestations such as stroke, encephalitis, and psychiatric conditions have been reported in COVID-19 patients, but the neurotropic potential of the virus is still debated. Herein, we sought to investigate SARS-CoV-2 infection in human neural cells. We demonstrated that SARS-CoV-2 infection of neural tissue is non-permissive, however, it can elicit inflammatory response and cell damage. These findings add to the hypothesis that most of the neural damage caused by SARS-CoV-2 infection is due to a systemic inflammation leading to indirect harmful effects on the central nervous system despite the absence of local viral replication.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Stem Cell Res Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Stem Cell Res Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido